Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report
TipRanks (Tue, 13-Jan 8:18 AM ET)
Business Wire (Fri, 9-Jan 11:00 AM ET)
Globe Newswire (Tue, 9-Dec 4:01 PM ET)
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson's Disease
Globe Newswire (Fri, 5-Dec 8:00 AM ET)
Amneal to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 2-Dec 8:00 AM ET)
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Globe Newswire (Tue, 2-Dec 8:00 AM ET)
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
Globe Newswire (Mon, 1-Dec 4:01 PM ET)
Amneal Receives U.S. FDA Approval for Iohexol Injection
Globe Newswire (Thu, 13-Nov 4:01 PM ET)
Amneal Reports Third Quarter 2025 Financial Results
Globe Newswire (Thu, 30-Oct 6:00 AM ET)
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Globe Newswire (Wed, 29-Oct 4:05 PM ET)
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Amneal Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol AMRX.
As of January 16, 2026, AMRX stock price climbed to $13.41 with 1,856,724 million shares trading.
AMRX has a beta of 0.81, meaning it tends to be less sensitive to market movements. AMRX has a correlation of 0.19 to the broad based SPY ETF.
AMRX has a market cap of $4.21 billion. This is considered a Mid Cap stock.
Last quarter Amneal Pharmaceuticals - Class A reported $785 million in Revenue and $.17 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.04.
In the last 3 years, AMRX traded as high as $13.49 and as low as $1.24.
The top ETF exchange traded funds that AMRX belongs to (by Net Assets): VTI, IWM, VB, VBR, VXF.
AMRX has outperformed the market in the last year with a price return of +63.1% while the SPY ETF gained +17.9%. AMRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +37.1% and +6.4%, respectively, while the SPY returned +4.3% and +1.4%, respectively.
AMRX support price is $12.97 and resistance is $13.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMRX shares will trade within this expected range on the day.